BioCentury
ARTICLE | Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

February 11, 2020 12:49 AM UTC

Updated interim data for Adverum’s intravitreal wet age-related macular degeneration gene therapy bolstered the company’s case that the product could compete with less convenient subretinal gene therapies for the indication.

Adverum rose $1.81 (18%) to $12.05 on Monday...